Zhejiang Yatai Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Zhejiang Yatai Pharmaceutical has been growing earnings at an average annual rate of 39.6%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 24.7% per year.
Key information
39.6%
Earnings growth rate
39.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -24.7% |
| Return on equity | -2.1% |
| Net Margin | -3.0% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zhejiang Yatai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 410 | -12 | 132 | 22 |
| 31 Dec 23 | 421 | -12 | 137 | 22 |
| 30 Sep 23 | 441 | -50 | 138 | 29 |
| 30 Jun 23 | 433 | -61 | 142 | 25 |
| 31 Mar 23 | 429 | -106 | 131 | 27 |
| 01 Jan 23 | 373 | -133 | 131 | 26 |
| 30 Sep 22 | 331 | -215 | 162 | 22 |
| 30 Jun 22 | 324 | -236 | 169 | 24 |
| 31 Mar 22 | 304 | -233 | 189 | 25 |
| 01 Jan 22 | 315 | -228 | 202 | 29 |
| 30 Sep 21 | 372 | 39 | 203 | 30 |
| 30 Jun 21 | 409 | 38 | 247 | 31 |
| 31 Mar 21 | 445 | 28 | 264 | 35 |
| 31 Dec 20 | 515 | 27 | 287 | 37 |
| 30 Sep 20 | 344 | -2,033 | 388 | 63 |
| 30 Jun 20 | 392 | -2,014 | 371 | 68 |
| 31 Mar 20 | 490 | -2,001 | 380 | 67 |
| 31 Dec 19 | 708 | -1,919 | 369 | 70 |
| 30 Sep 19 | 1,076 | 48 | 289 | 54 |
| 30 Jun 19 | 1,222 | 117 | 275 | 59 |
| 31 Mar 19 | 1,357 | 199 | 265 | 57 |
| 31 Dec 18 | 1,310 | 208 | 269 | 54 |
| 30 Sep 18 | 1,217 | 218 | 257 | 44 |
| 30 Jun 18 | 1,251 | 232 | 253 | 56 |
| 31 Mar 18 | 1,156 | 221 | 233 | 50 |
| 31 Dec 17 | 1,083 | 202 | 210 | 41 |
| 30 Sep 17 | 1,094 | 190 | 196 | 30 |
| 30 Jun 17 | 930 | 163 | 186 | 0 |
| 31 Mar 17 | 903 | 148 | 174 | 0 |
| 31 Dec 16 | 863 | 125 | 169 | 0 |
| 30 Sep 16 | 758 | 98 | 147 | 0 |
| 30 Jun 16 | 691 | 88 | 138 | 0 |
| 31 Mar 16 | 575 | 65 | 132 | 0 |
| 31 Dec 15 | 463 | 55 | 121 | 0 |
| 30 Sep 15 | 397 | 56 | 106 | 0 |
| 30 Jun 15 | 380 | 50 | 103 | 0 |
| 31 Mar 15 | 372 | 41 | 94 | 0 |
| 31 Dec 14 | 376 | 41 | 93 | 0 |
| 30 Sep 14 | 376 | 38 | 91 | 0 |
| 30 Jun 14 | 359 | 36 | 85 | 0 |
| 31 Mar 14 | 339 | 24 | 90 | 0 |
| 31 Dec 13 | 314 | 5 | 89 | 0 |
| 30 Sep 13 | 293 | -18 | 92 | 0 |
| 30 Jun 13 | 305 | -28 | 93 | 0 |
Quality Earnings: 002370 is currently unprofitable.
Growing Profit Margin: 002370 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002370 is unprofitable, but has reduced losses over the past 5 years at a rate of 39.6% per year.
Accelerating Growth: Unable to compare 002370's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 002370 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.1%).
Return on Equity
High ROE: 002370 has a negative Return on Equity (-2.12%), as it is currently unprofitable.